Login / Signup

A Predictive Autoantibody Signature in Multiple Sclerosis.

Colin R ZamecnikGavin M SowaAhmed AbdelhakRavi DandekarRebecca D BairKristen J WadeChristopher M BartleyAsritha TubatiRefujia GomezCamille FouassierChloe GerunganJessica AlexanderAnne E WapniarskiRita P LoudermilkErica L EggersKelsey C ZornKirtana AnanthNora JabassiniSabrina A MannNicholas R RaganAdam SantanielloRoland G HenrySergio E BaranziniScott S ZamvilRiley M BoveChu-Yueh GuoJeffrey M GelfandRichard CuneoH-Christian von BüdingenJorge R OksenbergBruce Ac CreeJill A HollenbachAri J GreenStephen L HauserMitchell T WallinJoseph L DeRisiMichael R Wilson
Published in: medRxiv : the preprint server for health sciences (2023)
Although B cells are implicated in multiple sclerosis (MS) pathophysiology, a predictive or diagnostic autoantibody remains elusive. Here, the Department of Defense Serum Repository (DoDSR), a cohort of over 10 million individuals, was used to generate whole-proteome autoantibody profiles of hundreds of patients with MS (PwMS) years before and subsequently after MS onset. This analysis defines a unique cluster of PwMS that share an autoantibody signature against a common motif that has similarity with many human pathogens. These patients exhibit antibody reactivity years before developing MS symptoms and have higher levels of serum neurofilament light (sNfL) compared to other PwMS. Furthermore, this profile is preserved over time, providing molecular evidence for an immunologically active prodromal period years before clinical onset. This autoantibody reactivity was validated in samples from a separate incident MS cohort in both cerebrospinal fluid (CSF) and serum, where it is highly specific for patients eventually diagnosed with MS. This signature is a starting point for further immunological characterization of this MS patient subset and may be clinically useful as an antigen-specific biomarker for high-risk patients with clinically- or radiologically-isolated neuroinflammatory syndromes.
Keyphrases